Transcriptional suppression of the miR-15/16 family by c-Myc in malignant pleural mesothelioma.

c-MYC mesothelioma microRNA transcriptional repression tumor suppressor

Journal

Oncotarget
ISSN: 1949-2553
Titre abrégé: Oncotarget
Pays: United States
ID NLM: 101532965

Informations de publication

Date de publication:
25 Jun 2019
Historique:
received: 12 02 2019
accepted: 04 05 2019
entrez: 11 7 2019
pubmed: 11 7 2019
medline: 11 7 2019
Statut: epublish

Résumé

MicroRNA downregulation is frequent in malignant pleural mesothelioma (MPM), but the mechanisms responsible for loss of miR-15/16 and miR-193a are yet to be elucidated and were investigated in this study. Copy Number Variation (CNV) of microRNA-coding genes was analyzed in MPM cells by digital droplet PCR (ddPCR) and revealed heterozygous loss of miR-193a and miR-15a/16-1, but no change in miR-15b/16-2. Epigenetic control of microRNA expression was inferred following decitabine and Trichostatin A (TSA) treatment which did not substantially affect microRNA expression. Knockdown of c-Myc expression led to upregulation of

Identifiants

pubmed: 31289611
doi: 10.18632/oncotarget.27010
pii: 27010
pmc: PMC6609241
doi:

Types de publication

Journal Article

Langues

eng

Pagination

4125-4138

Déclaration de conflit d'intérêts

CONFLICTS OF INTEREST The authors declare that they have no conflicts of interests.

Références

Methods. 2001 Dec;25(4):402-8
pubmed: 11846609
Proc Natl Acad Sci U S A. 2002 Nov 26;99(24):15524-9
pubmed: 12434020
Curr Biol. 2003 May 13;13(10):882-6
pubmed: 12747840
Oncogene. 2004 Feb 5;23(5):1088-97
pubmed: 14716294
Proc Natl Acad Sci U S A. 2004 Mar 2;101(9):2999-3004
pubmed: 14973191
J Cell Physiol. 2005 Jul;204(1):280-5
pubmed: 15648093
Nature. 2005 Jun 9;435(7043):834-8
pubmed: 15944708
Cancer Res. 2005 Nov 1;65(21):9628-32
pubmed: 16266980
Curr Top Microbiol Immunol. 2006;302:51-62
pubmed: 16620025
Proc Natl Acad Sci U S A. 2006 Jun 13;103(24):9136-41
pubmed: 16754881
Nat Rev Cancer. 2006 Nov;6(11):857-66
pubmed: 17060945
Blood. 2007 May 15;109(10):4399-405
pubmed: 17284533
Nat Genet. 2008 Jan;40(1):43-50
pubmed: 18066065
Am J Pathol. 2009 Mar;174(3):762-70
pubmed: 19218339
Nature. 2009 Apr 9;458(7239):762-5
pubmed: 19219026
J Clin Oncol. 2009 Apr 20;27(12):2081-90
pubmed: 19255316
Lung Cancer. 2010 Jan;67(1):57-68
pubmed: 19380173
Cell Death Differ. 2010 Feb;17(2):215-20
pubmed: 19498445
Cancer Res. 2009 Jul 1;69(13):5553-9
pubmed: 19549910
Cancer Res. 2009 Aug 15;69(16):6704-12
pubmed: 19654291
Cell Commun Signal. 2009 Aug 10;7:18
pubmed: 19664273
J RNAi Gene Silencing. 2009 Mar 09;5(1):321-30
pubmed: 19771229
Mol Cell. 2009 Oct 23;36(2):172-3
pubmed: 19854126
Mol Cancer. 2010 Apr 28;9:92
pubmed: 20426839
J Biol Chem. 2010 Jul 23;285(30):22809-17
pubmed: 20463022
Virchows Arch. 2011 Mar;458(3):313-22
pubmed: 21225432
Oncogene. 2011 Aug 4;30(31):3416-28
pubmed: 21399664
Lung Cancer. 2011 Sep;73(3):256-63
pubmed: 21620512
Clin Cancer Res. 2011 Aug 1;17(15):4965-74
pubmed: 21673066
Oncogene. 2012 Jun 14;31(24):3002-3008
pubmed: 22002311
Blood. 2012 Feb 2;119(5):1162-72
pubmed: 22096249
Clin Cancer Res. 2012 Mar 15;18(6):1619-29
pubmed: 22282464
EMBO Mol Med. 2012 Mar;4(3):143-59
pubmed: 22351564
Cancer Cell. 2012 Oct 16;22(4):506-523
pubmed: 23079660
Mol Oncol. 2012 Dec;6(6):590-610
pubmed: 23102669
Blood. 2013 Jan 17;121(3):499-509
pubmed: 23223432
Ann Oncol. 2013 Dec;24(12):3128-35
pubmed: 24148817
Lung Cancer. 2013 Dec;82(3):485-90
pubmed: 24168922
Cold Spring Harb Perspect Med. 2013 Dec 01;3(12):a014290
pubmed: 24296348
Oncogene. 2015 Mar 12;34(11):1393-406
pubmed: 24704828
J Thorac Oncol. 2014 Jul;9(7):998-1007
pubmed: 24926545
Nat Rev Mol Cell Biol. 2014 Aug;15(8):509-24
pubmed: 25027649
Oncotarget. 2015 Sep 15;6(27):23480-95
pubmed: 26125439
J Thorac Dis. 2015 Jun;7(6):1031-40
pubmed: 26150916
PLoS One. 2015 Sep 22;10(9):e0138560
pubmed: 26393798
Sci Transl Med. 2016 Mar 2;8(328):328rv4
pubmed: 26936508
Science. 2016 Apr 8;352(6282):227-31
pubmed: 26966191
Epigenomics. 2016 Aug;8(8):1079-85
pubmed: 27185582
J Cell Mol Med. 2016 Oct;20(10):1898-907
pubmed: 27241533
Microrna. 2017;6(1):2-16
pubmed: 27928946
Lancet Oncol. 2017 May;18(5):559-561
pubmed: 28495276
J Thorac Oncol. 2017 Sep;12(9):1421-1433
pubmed: 28629895
Lung Cancer. 2017 Aug;110:63-67
pubmed: 28676221
Theranostics. 2018 Jan 1;8(2):423-436
pubmed: 29290818
Cancer Immunol Immunother. 2018 Aug;67(8):1317-1324
pubmed: 29943157

Auteurs

Marissa Williams (M)

Asbestos Diseases Research Institute, Sydney, Australia.
Sydney Medical School, The University of Sydney, Sydney, Australia.

Yuen Yee Cheng (YY)

Asbestos Diseases Research Institute, Sydney, Australia.
Sydney Medical School, The University of Sydney, Sydney, Australia.

Michaela B Kirschner (MB)

Asbestos Diseases Research Institute, Sydney, Australia.
Current address: Department of Thoracic Surgery, University Hospital Zurich, Zurich, Switzerland.

Kadir H Sarun (KH)

Asbestos Diseases Research Institute, Sydney, Australia.

Karin Schelch (K)

Asbestos Diseases Research Institute, Sydney, Australia.
Current address: Institute of Cancer Research, Department of Medicine I, Medical University Vienna, Vienna, Austria.

Patrick Winata (P)

Asbestos Diseases Research Institute, Sydney, Australia.
Sydney Medical School, The University of Sydney, Sydney, Australia.

Brian McCaughan (B)

PAH Medical Centre, Sydney, Australia.

Steven Kao (S)

Asbestos Diseases Research Institute, Sydney, Australia.
Sydney Medical School, The University of Sydney, Sydney, Australia.
Chris O'Brien Lifehouse, Sydney, Australia.

Nico Van Zandwijk (N)

Asbestos Diseases Research Institute, Sydney, Australia.
Sydney Medical School, The University of Sydney, Sydney, Australia.
Current address: Sydney Local Health District, Concord, Australia.

Glen Reid (G)

Asbestos Diseases Research Institute, Sydney, Australia.
Sydney Medical School, The University of Sydney, Sydney, Australia.
Current address: Department of Pathology, University of Otago, Dunedin, New Zealand.

Classifications MeSH